CSBA Comments to Centers for Medicare & Medicaid Services (CMS) on Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026
April 14, 2023
The CSBA Board of Directors endorses BIO’s formal comments on
the Medicare Drug Price Negotiation Program, which are appended to this letter.
Download Full Comments Below
To protect patient access to critical prescription drugs, BIO has identified Part D guardrails (both MA-PD and PDP) for consideration as CMS develops guidance to plans for CY2025 and beyond.